Aug. 14 at 6:03 PM
$QUCY Colorectal Cancer Screening Divestiture
On March 28, 2026 the Company closed the sale of the ColoAlert assets to UTR, which included the ColoAlert intellectual property, customer-located instrumentation, and certain consumables, and included the transfer of two equipment lease obligations. The purchase price for the assets was
$348,966, which reduced the debt owed to UTR of
$648,966, resulting in a net payment to UTR of
$300,000 at closing.
On April 9, 2026, we entered into an asset purchase agreement (the “Agreement”) for the sale of the Next Gen IP to a third-party purchaser incorporated in Italy. Pursuant to the Agreement, we sold the Next Gen IP to the buyer for a payment of
$1.25 million. The sale of the Next Gen IP closed on April 20, 2026.
The transaction represents a strategic shift that has a major effect on the Company’s operations and financial results. Effective January 1, 2025, the colorectal cancer screening business’ financial results are discontinued operations
